Welcome to our dedicated page for SUPERNUS PHARMACEUTICALS SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SUPERNUS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SUPERNUS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Supernus Pharmaceuticals director Frederick M. Hudson reported a routine equity award conversion. On February 24, 2026, 4,475 restricted stock units were disposed back to the issuer at no cost, and he simultaneously acquired 4,475 shares of common stock at no cost.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, with settlement in stock scheduled to occur on February 19, 2026. After these transactions, Hudson directly holds 65,782 shares of common stock, reflecting a shift from derivative RSU holdings into outright share ownership rather than an open-market purchase or sale.
SUPERNUS PHARMACEUTICALS, INC. director Carrolee Barlow reported routine equity award activity. On February 24, 2026, 4,475 restricted stock units were disposed of back to the company as they converted into 4,475 shares of common stock at no cash cost. After this grant/award acquisition, Barlow directly owns 27,045 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Padmanabh P. Bhatt reported a series of equity-related transactions in connection with restricted stock units and common stock on February 24, 2026. He disposed of restricted stock units back to the issuer in amounts of 1,125, 750 and 1,250 units, each representing the right to receive one share of common stock upon vesting.
On the same date, he acquired common stock through grants or awards of 1,125, 750 and 1,250 shares. The filing also shows tax-withholding dispositions of 581, 354 and 646 common shares, with shares withheld by the company at prices of $51.35 and $50.86 per share to satisfy tax obligations upon RSU vesting. Certain RSUs vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, and are settled in common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported a mix of equity award activity and related share dispositions. On February 24, 2026, several restricted stock unit (RSU) awards vested, and RSUs totaling 1,125, 750 and 1,250 units were disposed of back to the company. Each RSU represents the right to receive one share of Supernus common stock upon vesting.
On the same date, Mottola received three common stock grants of 1,125, 750 and 1,250 shares at no cost, while 603, 368 and 670 common shares were delivered back to the company at prices of $51.35 and $50.86 to satisfy tax withholding obligations tied to the RSU vesting. The RSU awards vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, as applicable.
SUPERNUS PHARMACEUTICALS SVP and Chief Medical Officer Jonathan Rubin reported multiple equity compensation events. On February 24, 2026, restricted stock units were disposed back to the company as they vested, and corresponding shares of common stock were acquired. Some of these new shares were withheld by the company to cover tax obligations. The RSUs each convert into one share of common stock and vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025, depending on the grant.
SUPERNUS PHARMACEUTICALS, INC. director Georges Gemayel reported a mix of equity award activity and option exercises. On February 24, 2026, 4,475 restricted stock units were disposed of back to the issuer, while a matching 4,475 shares of common stock were acquired as a grant at no cost, bringing direct holdings in common stock to 38,159 shares.
On February 23, 2026, he exercised a director stock option for 15,000 shares of common stock at an exercise price of $12.98 per share, increasing his direct common stock ownership to 33,684 shares immediately after that exercise. Footnotes state each restricted stock unit represents one share of common stock and will settle in stock upon vesting on February 19, 2026.
Supernus Pharmaceuticals updated compensation for key executives following its annual review. The Board increased CEO Jack Khattar’s annual base salary from $1,036,000 to $1,067,100, awarded a 2025 cash bonus of $846,930, and granted options for 341,610 shares plus 204,966 performance share units that vest based on performance goals.
Other senior executives received base salary increases, 2025 cash bonuses, and equity awards combining stock options, restricted stock units, and performance share units. Option and RSU grants vest in equal annual installments over four years at an exercise price of $50.20 per share, while PSU vesting depends on performance as certified by the Compensation Committee.
Supernus Pharmaceuticals reported record revenue for both the fourth quarter and full year 2025 but moved from profit to loss due mainly to acquisition-related costs. Total revenues reached $211.6 million in Q4 2025, up 21% year over year, and $719.0 million for 2025, up 9%.
Growth products were the main driver, with combined revenues of $161.3 million in Q4 and $521.8 million for 2025, rising 45% and 40%. Newer assets performed strongly: ONAPGO generated $8.9 million in Q4 sales after its April launch and ZURZUVAE collaboration revenue was $32.8 million. However, 2025 GAAP operating results swung to a $62.3 million loss and net loss of $38.6 million, largely reflecting approximately $72.9 million in costs tied to the Sage Therapeutics acquisition and higher amortization and contingent consideration. Adjusted operating earnings were $158.7 million. Cash, cash equivalents and marketable securities were $308.7 million at year-end, after funding the Sage deal. For 2026, Supernus guides to total revenues of $840–$870 million, GAAP operating earnings of $0–$30 million, and adjusted operating earnings of $140–$170 million.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig reported a set of stock transactions involving restricted stock units and common shares of SUPN. On February 19, 2026, she exercised 4,475 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share as the units vested.
That same day, she conducted open-market sales of common stock in two blocks: 1,217 shares at a weighted average price of $50.31 (with individual trades between $49.83 and $50.71) and 3,258 shares at a weighted average price of $51.27 (with trades between $50.98 and $51.56). These sales, totaling 4,475 shares, were made under a Rule 10b5-1 trading plan adopted on May 15, 2025, and left her with 0 shares of common stock directly owned after the reported transactions.
Supernus Pharmaceuticals reported that Senior Vice-President & CFO Timothy C. Dec received new equity awards. He was granted employee stock options for 17,500 shares at a price of $0.00 per share, which vest in four equal annual installments beginning on February 18, 2027. He also received 3,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments starting on the same date and settled in common stock upon vesting. Following these awards, he directly holds 1,638 shares of common stock, including an aggregate of 392 shares acquired through the company’s Employee Stock Purchase Plan.